ArticleNPJ digital medicine2026
Explainable machine learning differentiates necrotizing fasciitis and osteomyelitis via routine blood biomarkers.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Necrotizing fasciitis (NF) and osteomyelitis (OM) are severe, limb-threatening infections with overlapping features, making early differentiation challenging. To address this, we developed and validated an explainable machine learning model using routine blood biomarkers from a retrospective, multi-center cohort of 3415 patients (579 NF, 2836 OM). Data from a primary center were used for model development, with data from a second center serving as an independent external testing cohort. Systematic evaluation identified an optimal 10-biomarker LightGBM model that achieved outstanding discrimination on the external cohort, with an AUC of 0.926. Beyond its high accuracy, explainability analyses confirmed the model's predictions are driven by robust, clinically relevant markers of severe inflammation and metabolic dysfunction, reinforcing its trustworthiness. The final model was deployed as a publicly accessible web tool for real-time risk stratification. This work provides a powerful, externally validated, and explainable AI framework to augment clinical judgment, with strong potential to reduce diagnostic delays and improve outcomes for these devastating infections.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.